<DOC>
	<DOC>NCT01093690</DOC>
	<brief_summary>The objective of this study is to assess the efficacy and tolerability of metoclopramide added to standard antiemetic regimen for prophylaxis of cisplatin-induced emesis.</brief_summary>
	<brief_title>Ondansetron Plus Dexamethasone With or Without Metoclopramide as Antiemetic Prophylaxis After Receiving Cisplatin</brief_title>
	<detailed_description>Ondansetron plus dexamethasone are standard emetic prophylactic agents for highly emetogenic chemotherapy. Metoclopramide is a dopamine antagonist, which may enhance efficacy of ondansetron and dexamethasone.</detailed_description>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Antiemetics</mesh_term>
	<mesh_term>Metoclopramide</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>schedule to receive first cycle of cisplatin &gt; 50 mg/m^2 pathologically or histologically confirmed solid cancer more than 18 years old creatinine clearance more than 50 ml/min aminotransferase less than 2 times of upper normal limit pregnant woman patients with episode of vomiting within 24 hours prior to chemotherapy session gut obstruction brain metastasis abdominal or pelvic irradiation no history of allergy to study drugs</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>chemotherapy induced nausea and vomiting, metoclopramide</keyword>
</DOC>